Circulating tumor cells in bladder cancer: Emerging technologies and clinical implications foreseeing precision oncology
Circulating tumor cells (CTC) in peripheral blood of cancer patients provide an opportunity for real-time liquid biopsies capable of aiding early intervention, therapeutic decision, response to therapy, and prognostication. Nevertheless, the rare and potentially heterogeneous molecular nature of CTC has delayed the standardization of robust high-throughput capture/enrichment and characterization technologies. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - March 9, 2018 Category: Urology & Nephrology Authors: Rita Azevedo, Janine Soares, Andreia Peixoto, Sofia Cotton, Lu ís Lima, Lúcio Lara Santos, José Alexandre Ferreira Tags: Review article Source Type: research

Does switching the bacillus Calmette-Gu érin strain affect clinical outcome in patients with recurrent non–muscle-invasive bladder cancer after initial bacillus Calmette-Guérin therapy?
It is still unknown whether switching the bacillus Calmette-Gu érin (BCG) strain at the second induction course of BCG therapy has a therapeutic benefit in patients with tumor recurrence after the initial BCG therapy (BCG-relapsing tumor). (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - March 9, 2018 Category: Urology & Nephrology Authors: Naoya Niwa, Eiji Kikuchi, Kazuhiro Matsumoto, Takeo Kosaka, Ryuichi Mizuno, Mototsugu Oya Tags: Original article Source Type: research

Circulating tumor cells in bladder cancer: Emerging technologies and clinical implications foreseeing precision oncology
Circulating tumor cells (CTC) in peripheral blood of cancer patients provide an opportunity for real-time liquid biopsies capable of aiding early intervention, therapeutic decision, response to therapy, and prognostication. Nevertheless, the rare and potentially heterogeneous molecular nature of CTC has delayed the standardization of robust high-throughput capture/enrichment and characterization technologies. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - March 9, 2018 Category: Urology & Nephrology Authors: Rita Azevedo, Janine Soares, Andreia Peixoto, Sofia Cotton, Lu ís Lima, Lúcio Lara Santos, José Alexandre Ferreira Tags: Review article Source Type: research

Does switching the bacillus Calmette-Gu érin strain affect clinical outcome in patients with recurrent non–muscle-invasive bladder cancer after initial bacillus Calmette-Guérin therapy?
It is still unknown whether switching the bacillus Calmette-Gu érin (BCG) strain at the second induction course of BCG therapy has a therapeutic benefit in patients with tumor recurrence after the initial BCG therapy (BCG-relapsing tumor). (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - March 9, 2018 Category: Urology & Nephrology Authors: Naoya Niwa, Eiji Kikuchi, Kazuhiro Matsumoto, Takeo Kosaka, Ryuichi Mizuno, Mototsugu Oya Tags: Original article Source Type: research

Prostate cancer management choices in patients undergoing multiparametric magnetic resonance imaging/ultrasound fusion biopsy compared to systematic biopsy
To assess management choices in patients who undergo magnetic resonance imaging (MRI)/ultrasound (MRI/US) fusion-guided prostate biopsy compared to patients who undergo systematic biopsy. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - March 8, 2018 Category: Urology & Nephrology Authors: Jennifer B. Gordetsky, Benjamin Saylor, Sejong Bae, Jeffrey W. Nix, Soroush Rais-Bahrami Tags: Original Article Source Type: research

The role of neural precursor cell-expressed developmentally down-regulated protein 9 in predicting bacillus Calmette-Guerin response in nonmuscle invasive bladder cancer
To report the sensitivity and specificity of neural precursor cell-expressed developmentally down-regulated protein 9 (NEDD9) protein high expression in predicting BCG response and its effect on recurrence or progression free survivals. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - March 5, 2018 Category: Urology & Nephrology Authors: Islam M. El-Babouly, Esam A.E. Desoky, Diab El Sayed, Maged M. Ali, Ola A. Harb, Ahmed Ragab, Ahmed M. Sakr, Amr M. Fawzi, Nashaat M. Salama, Ibrahim I. Samaha Tags: Original article Source Type: research

Conditional analyses of recurrence and progression in patients with TaG1 non –muscle-invasive bladder cancer
To determine conditional recurrence-free survival (RFS) and progression-free survival (PFS) and improve decision-making toward surveillance protocols and scheduling. Furthermore, evaluating the evolution of predictors for disease recurrence over time, because TaG1 non –muscle-invasive bladder cancer harbors a risk of disease recurrence and progression. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - March 2, 2018 Category: Urology & Nephrology Authors: Nicolas von Landenberg, Atiqullah Aziz, Friedrich C. von Rundstedt, Jakub Dobruch, Luis A. Kluth, Andrea Necchi, Aidan Noon, Michael Rink, Kees Hendricksen, Karel P.J. Decaestecker, Roland Seiler, C édric Poyet, Harun Fajkovic, Shahrokh F. Shariat, Evang Tags: Original article Source Type: research

Accurate prediction of progression to muscle-invasive disease in patients with pT1G3 bladder cancer: A clinical decision-making tool
To improve current prognostic models for the selection of patients with T1G3 urothelial bladder cancer who are more likely to fail intravesical therapy and progress to muscle-invasive bladder cancer (MIBC). (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - March 2, 2018 Category: Urology & Nephrology Authors: David D ′Andrea, Mohammad Abufaraj, Martin Susani, Robin Ristl, Beat Foerster, Shoji Kimura, Andrea Mari, Francesco Soria, Alberto Briganti, Pierre I. Karakiewicz, Killian M. Gust, Morgan Rouprêt, Shahrokh F. Shariat Tags: Original article Source Type: research

Conditional analyses of recurrence and progression in patients with TaG1 non –muscle-invasive bladder cancer
To determine conditional recurrence-free survival (RFS) and progression-free survival (PFS) and improve decision-making toward surveillance protocols and scheduling. Furthermore, evaluating the evolution of predictors for disease recurrence over time, because TaG1 non –muscle-invasive bladder cancer harbors a risk of disease recurrence and progression. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - March 2, 2018 Category: Urology & Nephrology Authors: Nicolas von Landenberg, Atiqullah Aziz, Friedrich C. von Rundstedt, Jakub Dobruch, Luis A. Kluth, Andrea Necchi, Aidan Noon, Michael Rink, Kees Hendricksen, Karel P.J. Decaestecker, Roland Seiler, C édric Poyet, Harun Fajkovic, Shahrokh F. Shariat, Evang Tags: Original article Source Type: research

Accurate prediction of progression to muscle-invasive disease in patients with pT1G3 bladder cancer: A clinical decision-making tool
To improve current prognostic models for the selection of patients with T1G3 urothelial bladder cancer who are more likely to fail intravesical therapy and progress to muscle-invasive bladder cancer (MIBC). (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - March 2, 2018 Category: Urology & Nephrology Authors: David D ′Andrea, Mohammad Abufaraj, Martin Susani, Robin Ristl, Beat Foerster, Shoji Kimura, Andrea Mari, Francesco Soria, Alberto Briganti, Pierre I. Karakiewicz, Killian M. Gust, Morgan Rouprêt, Shahrokh F. Shariat Tags: Original article Source Type: research

Acetyl-CoA synthetase 2 enhances tumorigenesis and is indicative of a poor prognosis for patients with renal cell carcinoma
Acetyl-CoA synthetase 2 (ACSS2) is highly expressed in various cancers, whereas ACSS2 expression and function in renal cell carcinoma (RCC) are unknown. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - March 1, 2018 Category: Urology & Nephrology Authors: Shaojin Zhang, Juanjuan He, Zhankui Jia, Zechen Yan, Jinjian Yang Tags: Original article Source Type: research

Null association between androgen-deprivation therapy and nonprostate cancer mortality among older men with nonmetastatic prostate cancer
Androgen-deprivation therapy (ADT) has been associated with cardiovascular risk factors and the development of cardiovascular disease in men with metastatic prostate cancer. We sought to examine the effect of ADT on nonprostate cancer mortality among patients with nonmetastatic prostate cancer. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - March 1, 2018 Category: Urology & Nephrology Authors: Christopher J.D. Wallis, Raj Satkunasivam, Sender Herschorn, Calvin Law, Arun Seth, Ronald T. Kodama, Girish S. Kulkarni, Robert K. Nam Tags: Original article Source Type: research

Acetyl-CoA synthetase 2 enhances tumorigenesis and is indicative of a poor prognosis for patients with renal cell carcinoma
Acetyl-CoA synthetase 2 (ACSS2) is highly expressed in various cancers, whereas ACSS2 expression and function in renal cell carcinoma (RCC) are unknown. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - March 1, 2018 Category: Urology & Nephrology Authors: Shaojin Zhang, Juanjuan He, Zhankui Jia, Zechen Yan, Jinjian Yang Tags: Original article Source Type: research